Randomized Trial of Creatine-kinase Leak After Rosuvastatin At the Time of Percutaneous Coronary Intervention

Exclusion Criteria

• •Women of childbearing potential who are not using appropriate contraceptive measures during pregnancy and lactation .
• •Values above the upper limit of normal serum levels of CK-MB mass harvested 24 hours prior to the procedure.
• •Myocardial infarction \< 15 days.
• •Renal insufficiency with creatinine clearance \< 30 ml/min
• •Patients with known allergy, hypersensitivity or contraindication to any of the following: aspirin , heparin , clopidogrel , ticagrelor , and statin or iodinated contrast .
• •Participation in other research to influence serum levels of CK-MB mass
• •Have taken fibrate 24 hours before the intervention .
• •Use of oral anticoagulants or glycoprotein inhibitors at the day of the procedure .
• •Evidence of angiographic intracoronary thrombus in the target lesion .
• •In -stent restenosis , vein graft or arterial .
• •Complications of the procedure as irreversible occlusion of the target vessel as well as branch greater than 1mm in diameter , presence of dissection with compromised flow, caging branch with reduced flow , coronary spasm with abnormal blood flow and distal embolization .
• •Inability to deploy stent .
• •Use of atherectomy technique .
• •Patients were randomized to rosuvastatin be administered prior to the procedure , having the guidewire stent reached the ostium of the coronary target with time less than two hours or having exceeded the period of six hours after oral ingestion.